

medEctoin®




pharma-grade Ectoin

- medEctoin® is a clinically studied and proven, very tolerable substance for the use in the pharmacuetical industry, healthcare products and as a substance in medical devices (OTC).
- It is a cyclic amino acid derivate with highly effective inflammation-reducing and membrane-stabilizing properties. The efficacy of **medEctoin®** has been proven in over 40 clinical trials.
- **medEctoin**[®] is the only "Made in Germany" and 100% natural ectoine in the market qualified for the use in pharmaceutical and healthcare products and as a substance in medical devices (OTC).

Trade name	medEctoin®
INCI name	Ectoin
Chemical name	(4S)-2-methyl-1,4,5,6-tetra-hydropyrimidine-4-carboxylic acid
CAS No.	96702-03-3
EINECS / EC No.	431-910-1
REACH No.	01-0000017811-72-0001
Description	Cyclic amino acid derivate
Structure	H, c H C00-
Level of use	0.5% - no upper limit
Product of use	Pharmaceuticals, Healthcare Products, Medical Devices (OTC)
Certifications	NATRUE, COSMOS, EcoCert
Application media	Water phase
Stability	pH 1-9, very high temperatures (>85°C), sub-zero temperatures (e.g. freeze-drying); light stable, stable against oxygen
Solubility	Excellent solubility in water (~ 550 g/l); glycerin
Shelf life	> 5 years
Preservation	Preservative free
Origin	Manufactured by a biotechnological manufacturing process (fermentation) according to EN ISO 13485 at the bitop AG plant in Dortmund, Germany.
Pack units	1kg (wide-mouth PE bottle) , 5kg, 10kg (PE bag in cardboard packaging), 25kg (PE bag in hobbock on euro palette)







Studies conducted with medEctoin® in Healthcare Products (OTC)

Indication	Studies	Patients	Main Outcome
Allergy	<10	<650	 Improvement of local symptoms of eye & nose As effective as standard drugs
Airway Diseases	4	393	 Reduction of specific inflammation markers (Asthma/ COPD) Significant improvement of asthma symptoms Reduction of Bronchitis symptoms
Cough & Cold	6	520	 Nose: reduction of rhinitis & rhinosinusitis, very good sensoric properties Throat: significant reduction of lymph node swelling
Dry Eyes Dry Nose	<10	>1.000 (eye)	 Eyes: significant improvement of TBUT, non inferior to HA eye drops, improvement of wound healing, reduction of non specific inflammation Nose: improvement of combined dry nose symptoms score
Dermatology	>15	6 with MD >9 with Cosmetics	 Reduction of of local Atopic Dermatitis symptoms, erythema, TEWL, irritation score, dryness, scaling (N>500) Reduction of local Psoriasis symptoms (N>90) Anti Aging / stress protection efficacy (N>400)
Supportive Care	1	3 case series >60 patients	 Reduction of oncology treatment reduced inflammatory response Prophylactic and therapeutic reduction of mucositis symptoms
Gynecology and Women's Health	1	>200	 Long term hydration and regeneration of vaginal mucosa Superior treatment of Vaginal atrophy and vaginal dryness compared to Hyaluronic Acid



Scan to contact our sales team



Let's talk

bitop AG Carlo-Schmid-Allee 5 44263 Dortmund bd@bitop.de www.bitop.de







